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Abstract
Effective treatment for pancreatic cancer remains challenging, particularly the treatment of pancreatic ductal adenocarcinoma
(PDAC), which makes up more than 95% of all pancreatic cancers. Late diagnosis and failure of chemotherapy and radiotherapy
are all too common, and many patients die soon after diagnosis. Here, we make the case for the increased use of molecular
imaging in PDAC preclinical research and in patient management.
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Introduction
Effective treatment for pancreatic cancer remains challenging,
particularly the treatment of pancreatic ductal adenocarcinoma
(PDAC), which makes up more than 95% of all pancreatic
cancers. Although research effort has recently been stepped
up, the average 5-year survival following the diagnosis of
PDAC is a dismal 5% and has not changed at all over the past
40 years. In excess of 50,000 patients were diagnosed with
PDAC in the EU in 2012, with nearly as many dying from the
disease (source: Cancer Research UK). Radical surgery
followed by adjuvant chemotherapy remains the mainstay of
curative treatment and is associated with a median overall
survival of 28 months, very low compared with that of other
cancers. As patients with PDAC often present with vague or
nonspecific symptoms, the disease frequently remains unde-
tected until the later stages when invasion of the surrounding
vasculature or the presence of metastases prevent radical ther-
apy. In these patients, innate resistance to chemotherapy and
radiotherapy are all too common, and many die soon after
diagnosis (Cancer Research UK, Pancreatic Cancer UK, and
[1]). Nuclear medicine imaging and radionuclide therapy in
pancreatic neuroendocrine tumours (P-NETs) have been de-
scribed in great detail elsewhere [2]. PDAC, originating from
the exocrine part of the pancreas is markedly distinct from
exocrine PDAC tumours. P-NETs are much more rare, and
have a more favourable diagnosis. Here, we make the case
for the increased use of nuclear medicine imaging in PDAC
preclinical research and in patient management.
Given the late presentation with inoperable disease and
poor response to chemo(radio)therapy, there is a clear
need for early detection methods, as well as for early
and accurate therapy response assessment, so that clinical
decisions can be made expeditiously. It is in these aspects
that molecular imaging, using techniques such as PET and
SPECT, can make a significant difference. The current
paradigm for pancreatic cancer care mainly relies on ana-
tomical imaging using ultrasonography, CT and MRI, and
on obtaining confirmatory biopsies of the tumour. The
disadvantage of these imaging approaches is that differen-
tiation between malignant lesions and nonmalignant cysts
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is challenging, especially for smaller lesions [3]. Because
PET and SPECT imaging can provide functional informa-
tion about a tumour via its unique biomarker expression,
they can be considered complementary to the above tech-
niques and can overcome several of their inherent
disadvantages.
Treatment stratification and targeted therapy based on
pathological/molecular parameters are revolutionizing the
management of many different cancers. Yet, management of
pancreatic cancer continues to challenge medical profes-
sionals, largely because of the diversity of the pathways that
drive this cancer. Moreover, the challenges of obtaining ade-
quate tissue from the tumour itself given its deep-seated posi-
tion within the body make serial biopsies to assess treatment
effects rather impractical. Sampling from a single tumour site
ignores the possible extent of tumour heterogeneity and the
existence of metastasis with a different genetic and phenotypic
make-up. Again, molecular imaging can overcome these lim-
itations, and complement ongoing efforts.
On the whole, biomarkers for pancreatic cancer are
underexplored and those few that are in use, such as expres-
sion levels of CA19.9 or CEA in blood plasma, are signifi-
cantly lacking in specificity and sensitivity. Hence, alternative
biomarkers are much sought after. A recently published report
suggests that a new mixed analyte blood test is more promis-
ing [4]. Although this particular test was shown to be able to
effectively highlight possible pancreatic malignancy (in ap-
proximately 80% of patients, with a specificity of more than
99%), a blood test is unable to reveal either the anatomical
location or the extent of the disease. Such a blood test, in
conjunction with sensitive noninvasive molecular imaging
aimed at detecting early cancerous lesions, could provide a
more effective strategy for early diagnosis. Moreover, the
use of molecular tracers helps realize imaging-based measures
of functional pathways targeted by treatment, and could there-
fore provide a means to determine treatment response. Several
molecular imaging strategies for PDAC are in use in the clinic
or are in clinical trials, and several new molecular imaging
strategies have been proposed in the literature, but still remain
in the preclinical research stage, as described below.
Clinical molecular imaging of PDAC (PET)
18F-FDG
18F-FDG PET imaging, the mainstay of PET imaging, has
been considered for a long time to inform the diagnosis of
PDAC. Most PDAC tumours have a high metabolic rate and
their 18F-FDG uptake increases throughout disease progres-
sion from pancreatic intraepithelial neoplasia (PanIN) precur-
sor lesions (PanIN-1 to PanIN-3) up to PDAC (the canonical
PDAC tumour progression model) [5, 6]. Over 90% of PDAC
tumours carry a mutation in the KRAS oncogene, which pro-
motes glucose uptake via upregulation of hexokinase-2 and
the glucose transporter [7]. Clinically, 18F-FDG uptake in
PDAC is considered valuable in treatment selection (Fig. 1).
Some guidelines suggest that 18F-FDG PET has a very limited
or no role in the diagnosis or prognosis of PDAC [8, 9], al-
though there are a number of reports of the superiority of 18F-
FDG PET/CT in the detection of PDAC over contrast-
enhanced CT and MRI [7].
Patients presenting with multiple 18F-FDG-avid foci
representing metastatic disease are considered unsuitable for
surgery, and are treated palliatively with chemotherapy. In the
PET-PANC study (one of the larger studies of its kind, which
prospectively evaluated the benefits of PET/CT imaging in
589 patients with PDAC across multiple hospitals in the
UK), the use of 18F-FDG PET/CT influenced management
in 45% of patients and led to the avoidance of unnecessary
surgery in 20% of patients [10]. Unfortunately, the occurrence
of pancreatitis may complicate the interpretation of 18F-FDG
PET images as this inflammatory response, which coinciden-
tally plays a significant role in PDAC tumorigenesis [11], can
also lead to 18F-FDG-avid foci. This effect is especially strong
in the case of groove, autoimmune, and focal pancreatitis [12],
and complicates the differentiation of PDAC from these more
benign conditions. Also, glucose intolerance is a frequent
complication in patients with PDAC, and high glucose levels
can decrease 18F-FDG uptake in the tumour. Preclinical and
preliminary clinical data further suggest that 18F-FDG PET
cannot reliably be used for the evaluation of therapy response
following chemotherapy or chemoradiotherapy [13, 14].
18F-FLT
The ability of [18F]-3′-fluoro-3′-deoxy-L-thymidine (18F-
FLT), an imaging agent designed to measure cell proliferation,
to image PDAC has also been evaluated. 18F-FLT is an ana-
logue of the nucleotide thymidine, which is generally taken up
in highly proliferative tissues [15]. 18F-FLT has been evaluat-
ed as an early predictor of disease progression in patients with
advanced and metastatic pancreatic cancer, but assessment of
especially liver metastases may be hampered by high back-
ground hepatic activity due to 18F-FLT glucuronidation [16,
17]. Early data from Quon et al. indicate that generally low
18F-FLT PET tumour uptake results in poor lesion detectabil-
ity [18], suggesting that 18F-FLT is not a good alternative to
FDG for PET imaging. A recent study byWieder et al. looked
at the ability of 18F-FLT PET imaging to identify those pa-
tients with known tumours who might fare worse [19]. In a
small cohort of 27 patients, they found that 18F-FLT uptake in
the tumour was correlated significantly with survival (hazard
ratio 1.298, 95% CI 1.001–1.685; p < 0.05). An example of a
patient with high 18F-FLT uptake in the tumour is shown in
Fig. 2. They concluded that, although 18F-FLT PET is a poor
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diagnostic imaging method, it may allow risk stratification in
patients with resectable pancreatic cancer prior to surgery.
Hypoxia
PDAC is generally believed to be unusually hypoxic, which
contributes to the poor response to chemotherapy and radio-
therapy [20]. Although the exact causes of this hypoxic phe-
notype are not entirely understood, it is known that PDAC is a
particularly poorly vascularized tumour. Additionally, the ex-
aggerated desmoplastic response in PDAC is thought to
contribute to the hypoxic state, and in turn, to hypoxia-
enhancing desmoplasia. The term ‘desmoplasia’ denotes the
extensive fibroblastic cell proliferation surrounding the PDAC
cell glands, containing extracellular matrix proteins,
myofibroblastic pancreatic stellate cells and immune cells.
Together, they modulate PDAC growth by providing a scaf-
fold for the cancer cells to grow, as well as growth factors and
immune modulators [21]. The mere denseness of the dense
desmoplastic reaction prevents oxygen diffusion, but signal-
ling within this microenvironment also contributes to its own
advance. For example, pancreatic stellate cells, which make
Fig. 2 18F-FLT PET image in a
70-year-old patient with a 2-cm
tumour in the pancreatic head [19]
Fig. 1 18F-FDG PET imaging for
initial staging of PDAC in an 80-
year-old woman. a The initial
staging MR image shows a
hypoenhancing mass in the pan-
creatic body (arrows) that has re-
sulted in pancreatic ductal dilata-
tion. b The PET/CT image shows
corresponding FDG uptake in the
mass (arrows). c, d Additionally,
the fused PET/CT image (c) and
PET-only image (d) show an 18F-
FDG-avid peripancreatic node
(arrows). Adapted from Yeh et al.
[7]
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up the bulk of the stroma, under hypoxic conditions stimulate
the production of endostatin, an angiostatic factor, by pancre-
atic cancer cells, thereby reducing angiogenesis and enhanc-
ing hypoxia. Also the stroma of PDAC tissue is often hypoxic.
These oxygen-lacking tumour areas, at least in mouse models
of PDAC, are highly glycolytic and release lactate, which is
metabolized by nearby normoxic cancer cells to sustain pro-
liferation. This particularly hypoxic microenvironment is
thought to play a significant role in the poor outcome of
PDAC patients due to induction of epithelial-to-
mesenchymal transition that promotes early metastasis [20].
These considerations provide the rationale for imaging
hypoxia using the well-known nitroimidazole-based hypoxia
imaging agents, 18F-FMISO and 18F-FAZA (18F-HX4 has al-
so been used by some groups). Yet hypoxia in PDAC tumours
is highly heterogeneous, and hypoxia imaging in PDAC is
hindered by a propensity to reach diffusive equilibrium only
slowly [22, 23]. 18F-FMISO uptake in proven PDAC has been
correlated with a worse prognosis [24], although 18F-FMISO
uptake in PDAC is rather limited, with tumour-to-blood ratios
of 1.2:1 generally considered as indicative of hypoxia. The
same is true for 18F-FAZA [23]. 18F-HX4 may lead to higher
ratios, with ratios between 1.3 and 2.1 reported [25]. Certainly,
more research is needed to define the exact role of hypoxia
imaging in the management of patients with PDAC.
Antibodies
Radiolabelled antibody-based imaging of pancreatic tumours
in patients was reported as early as 20 years ago in a study in
which mucins were targeted using a murine anti-Nd2 antibody
[26]. The authors showed a good correlation between pancre-
atic uptake, measured by planar scintigraphy, and immuno-
staining of excised pancreatic tumorous tissue by Nd2.
However, there was little correlation with CEA or CA19.9
plasma levels. They also concluded that Nd2 imaging could
differentiate exocrine pancreatic tumours from benign lesions
and PDAC. However, since then, hardly any clinical follow up
studies have been performed [27]. One of the few studies
investigated the use of 111In-labelled amatuximab in
mesothelin-expressing cancers [28]. Although antibodies and
their fragments hold great potential as the basis for PDAC-
imaging agents, given their unrivalled selectivity and affinity,
the main challenges in clinical translation of antibody-based
imaging continue to be: (1) the cost of producing antibodies in
reliable quantities to the required quality standard, (2) the
presence of the enhanced perfusion and retention (EPR) effect
that causes nonselective extravasation and uptake in tumours
with hyperfenestrated vasculature, (3) trapping of antibodies
by the reticuloendothelial system that leads to hepatic and
splenic uptake, complicating differentiation of primary
PDAC and hepatic metastases from physiological uptake,
and (4) the lack of chemistry that would allow fast, site-
selective and thermodynamically stable radiolabelling of the
antibody vector [29, 30]. However, the advent of immunother-
apy and its increased deployment in the clinic hails a new start
for immuno-PET imaging in which there is increased interest
and development.
Preclinical molecular imaging of pancreatic
cancer
Despite there being several imaging agents under evaluation
for the management of patients with PDAC (see above), there
is most certainly a need for more and better agents. For exam-
ple, several epitopes and signalling pathways have been
under-explored so far, even preclinically, as molecular imag-
ing targets. Hence, molecular imaging of PDAC merits pre-
clinical exploration, including exploration of targets for the
tumour stroma [31], cell–cell interactions [32], and PDAC’s
inflammatory microenvironment [33]. There is still much
room for expansion of metabolic imaging agents for use in
PET – and SPECT – as agents targeting aberrant PDAC cell
signalling (reviews include [34–36]). The most studied signal-
ling pathway in PDAC is without doubt the RAS-RAF-
MAPK pathway, given the near universal mutation of
KRAS in PDAC, yet molecular imaging of this crucial signal-
ling axis has so far proven elusive. Other pathways of interest
include p53 and SMAD4 signalling, both often mutated in
PADC, as well as notch, IGF and WNT signalling [36–38].
Imaging of PDAC, by contrast, focuses mostly on the extra-
cellular changes that arise during PDAC development. Here,
we give an overview of some of the radiolabelled imaging
agents that have already been evaluated.
GRP78
GRP78 is a 78-kDa glucose-regulated protein that is known
to control structural maturation of glycoproteins. However,
it is also expressed on the cell surface where it acts as a
receptor for a wide variety of ligands and as an autoantigen
[39]. GRP78 has also been described as a receptor of angio-
genic peptides and is known to interact with major histo-
compatibility complex class I. Cell-surface GRP78 expres-
sion has been detected in many different cancers, such as
breast, liver, prostate, and pancreatic tumour tissue, and has
been associated with the development of drug resistance
and cell transformation [40, 41].
The use of anti-GRP78 antibodies in anticancer therapy is
being explored given their ability to suppress a wide variety of
xenograft tumours by inhibiting PI3K/AKT signalling and by
inducing apoptosis [42]. Wang et al. described a 64Cu-labelled
anti-GRP78 monoclonal antibody, MAb159, which binds to
GRP78 with an affinity in the low nanomolar range (Kd =
1.7 nM) [43, 44] Although only modest tumour uptake was
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observed in GRP78-overexpressing BxPC-3 xenografts in
mice (18 ± 1.0%ID/g at 48 h after injection; Fig. 3), no uptake
above EPR was observed for a 64Cu-labelled nonspecific
isotype control antibody, suggesting that labelled antibodies
such as this one may have translational potential.
Transferrin
The transferrin receptor 1 (TfR1, or CD71) is significantly
involved in iron homeostasis and proliferation [45]. This
cell membrane receptor binds to iron-loaded transferrin to
import iron into the cell. Upon endocytosis, iron is released
and the receptor–transferrin complex is recycled back to the
cell surface. The transferrin receptor is a marker of a malig-
nant phenotype in PDAC [46], its expression correlates with
a worse prognosis. It is also thought to modulate mitochon-
drial respiration and generation of radical oxygen species
[47]. The advantage of transferrin receptor imaging is that it
may also have applications in the detection of pancreatic
neuroendocrine and lung cancer.
Holland et al. used transferrin itself to target the transferrin
receptor in a glioblastoma xenograft mouse model [48, 49].
They found tumour uptake of >10%ID/g at 24 and 48 h after
administration of 89Zr-transferrin, also labelled using the iron-
binding siderophore desferrioxamine (DFO) as a metal ion
chelator rather than relying on the transferrin itself to bind to
the 89Zr4+ ion. This compound may therefore also hold prom-
ise for PDAC imaging.
Pirollo et al. generated what they called a ‘nanodelivery
platform’ for MRI imaging of transferrin comprising an
antitransferrin receptor single-chain antibody fragment linked
to a liposomal nanoparticle containingGd-DTPA (Fig. 4) [50].
They found increased uptake in PDAC xenografts in mice,
and improved lesion delineation, but unfortunately did not
quantify their results. Sugyo et al. used a 89Zr-labelled anti-
transferrin receptor monoclonal antibody (TSP-A01) for PET
imaging in MiaPaCa-2 xenograft-bearing mice as a precursor
for antitransferrin receptor immunotherapy [51]. Tumour up-
take was relatively modest (for an antibody) at 12 ± 2.3%ID/g
at 48 h after intravenous injection but provided the necessary
contrast for lesion visualization.
Mesothelin
Mesothelin is a 40-kDa transmembrane protein that is normal-
ly expressed in mesothelial cells where it activates STAT,
AKT and MAPK signalling pathways [52]. Under physiolog-
ical conditions, mesothelin is expressed at relatively low
levels, but is overexpressed in virtually all malignant meso-
theliomas as well as in pancreatic adenocarcinomas. One
study even found mesothelin expressed in 60 out of 60 human
PDAC samples [53], and the extent of overexpression proved
a strong predictor of a worse prognosis. Importantly,
mesothelin is not detected in normal, healthy pancreas [52].
It is therefore no surprise that mesothelin is being investigated
as a target for immunotherapy in ongoing clinical trials eval-
uating among other approaches antibody–drug conjugates in-
cluding anetumab ravtansine [54].
Lamberts et al. used an antimesothelin antibody for PET
imaging of PDAC to prove delivery of the antibody to tumour
tissue. Using the anti-mesothelin antibodyAMA radiolabelled
with 89Zr using a DFO chelator, they found uptake in HPAC
and CAPAN-2 xenografts of up to 12%ID/g 6 days after in-
jection. The authors went on to use a similar construct in
patients with ovarian cancer or PDAC before treatment with
a mesothelin-targeting antibody–drug conjugate (Fig. 5) [55].
The mean SUV in PDAC tumours was 11.5, although some
lesions showed SUVs as high as 20 and as low as 5, with
relatively high uptake in normal tissue uptake found, as ex-
pected, (mean SUVmax approximately 14 in the liver).
Integrins: αvβ6, αvβ3
Integrin expression has been targeted since the late 1990s for
molecular imaging using peptides containing the tripeptide
RGD sequence which binds preferentially to integrins αvβ3,
αvβ5 andαvβ6 [57], an interaction that had been known about
for a decade previously. For an excellent review of this partic-
ular topic, see reference [58]. A wide variety of MRI, optical
and radiolabelled imaging agents have been developed to tar-
get integrins over the years, mostly focusing on αvβ3 in the
context of tumour neovascularization [59]. The latter can be
targeted by RGD peptide-based imaging agents, although this
is not specific for the αvβ6 overexpressed in PDAC [60], and
that has been pursued for therapeutic benefit in that setting
[61]. The use of antibodies and peptides against αvβ6 for
PDAC therapy is being investigated, with promising results
reported with the combination of antibody therapy and
gemcitabine in a mouse model [62].
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Fig. 3 Coronal PET image of a mouse bearing a GRP78-positive BxPC-3
tumour xenograft 48 h after injection of the 64Cu-labelled anti-GRP78
antibody MAb159 [44]
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One αvβ6-targeting compound,
68Ga-avebehexin, com-
prises a triazacyclononane-triphosphinate (TRAP) chelator
for 68Ga labelling, linked to three αvβ6 integrin-selective cy-
clic nonapeptides [63]. This conjugate was specifically taken
up by αvβ6-expressing H2009 lung cancer cells, with uptake
of around 0.65%ID/g, with some specific uptake in the stom-
ach (0.52%ID/g) and intestines, but negligible uptake in
healthy murine pancreas (0.07%ID/g; Fig. 6). However, sim-
ilar contrast was obtained targeting αvβ3 using
68Ga-
NODAGA-RGD in a genetically engineered spontaneous
mouse model of PDAC, the KPC model [60, 64]. Whether
αvβ6 orαvβ3 is the optimal target for PDAC imaging remains
to be determined.
Tissue factor
Overexpression of tissue factor (TF, CD142) has been associ-
ated with increased tumour growth, tumour angiogenesis, and
metastatic potential in many malignancies, including pancre-
atic cancer, and soluble TFmay also contribute to activation of
the coagulation system in pancreatic cancer [65]. Its physio-
logical functions include the processing of prothrombin to
thrombin, an essential factor in blood clotting. Hernandez
et al. synthesized a 89Zr-labelled anti-TF monoclonal anti-
body, ALT-836. They observed very good uptake in BxPC-3
TF-overexpressing tumours (32 ± 6.0 %ID/g) in contrast to
2.3 ± 0.5%ID/g in tumours in which specific uptake was
blocked by an excess of cold, unlabelled antibody [66]. The
uptake of ALT-836 was much higher than that of an earlier
64Cu-labelled version (15%ID/g) [67]. Takashima et al. used
another anti-TF antibody (clone 1849) labelled with 111In to
image orthotopic gliomas, with similar results [68].
Neurotensin receptors
Neurotensin is a 13 amino acid peptide first isolated in 1973
from bovine hypothalamus [69]. It is normally present in the
gastrointestinal tract and the brain, where it is thought to trig-
ger a wide variety of central and peripheral functions through
its interaction with three neurotensin (NTS, or NT) receptors:
NTSR1, NTSR2, and NTSR3. NTSR1 is a G protein-coupled
transmembrane protein whose functions include blood pres-
sure, blood sugar and temperature homeostasis. NTSR1 is
known to be overexpressed in PDAC primary and metastatic
tumour masses, as well as in high-grade PanINs [70], and also
in prostate and colorectal cancer. For this reason, it too has
been targeted for molecular imaging with radiopharmaceuti-
cals for quite some time.
Imaging of NTSR1 (also sometimes called NTR) has often
been based on NTS, the natural ligand. The main challenge
here is that the C-terminal NTSR1 binding domain NTS(8–
13) is rapidly degraded in vivo by endogenous peptidases.
Therefore, efforts have focused on the introduction of non-
natural amino acids or variation of the amino bonds to prevent
Fig. 5 aMesothelin in PDAC
(protein atlas: 11/12 positive
[56]). b 89Zr-MMOT0530 PET/
CT image in a patient with PDAC
shows the primary tumour (red
oval), as well as uptake in healthy
liver [55]
Baseline Free Magnevist Nanocomplex-MagFig. 4 MRI imaging in an
orthotopic mouse model of
pancreatic cancer 4 months after
surgical implantation of the
tumour showing the difference in
signal between intravenously
administered conventional
contrast agent (free Magnevist)
and the TfRscFv-Lip-Mag com-
plex [50]
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degradation while preserving affinity of the molecule for
NTSR1 [71]. One successful example from amongst a multi-
tude of studies is a systematic study of the NTSR1 and
NTSR2 binding affinity of a dozen compounds labelled with
18F or 68Ga. One of these peptides showed acceptable NTSR1
selectivity (fourfold higher affinity for NTSR1 than for
NTSR2). Tumour uptake and pharmacokinetics were evaluat-
ed in vivo (Fig. 7), and the tracer showed uptake of up to 1.6 ±
0.35%ID/g in HT29 colorectal adenocarcinoma tumours, pro-
viding excellent contrast with respect to normal tissue (tu-
mour-to-blood ratio 31, tumour-to-muscle ratio 3.2) [71].
Another set of NTSR1 imaging agents is based on small-
molecule NTSR antagonists, such as SR142948A. One exam-
ple was labelled though a Cu-assisted click reaction with 18F-
2-deoxy-2-fluoroglucosyl azide [72]. The authors showed
good receptor affinity of around 0.98 nM (Kd), and HT29
tumour xenograft uptake in mice of up to 0.7%ID/g, with
much lower uptake in most normal tissues, at 1 h after injec-
tion. Unfortunately, intestinal uptakewas high, possibly due to
hepatobiliary excretion, potentially limiting applications for
the imaging of stomach and pancreatic tumours.
Cathepsins
In the pancreas, cathepsin E is not expressed in normal
healthy tissue, but is present in nearly all PDAC tissue.
Cathepsins are a family of proteases implicated in the regu-
lation of angiogenesis and invasion during cancer progres-
sion, and are highly upregulated in pancreatic cancer, con-
tributing to the development and progression of the cancer
phenotype [73]. A Cy5 fluorophore-labelled cathepsin E
substrate was developed as an imaging probe by Cruz-
Monserrate et al. [74]. They showed uptake of the labelled
substrate in MDA PATC-3 murine PDAC cells, as well as
PDAC tumours in KPC mice, with PanIN precursor lesions
showing slightly lower uptake (Fig. 8).
In addition, the role of cathepsin B as a driver of tumour
progression in pancreatic cancer has been demonstrated [76].
This was exploited by Kramer et al. who developed a cathep-
sin B-binding DARPin, an ankyrin repeat protein, with very
high affinity (Kd = 35 pM). When tagged with the fluorophore
Cy5.5, this DARPin (8h6) was taken up in cathepsin B-
positive 4T1 subcutaneous allografts [75]. The lack of
radionuclide-labelled imaging agents makes direct compari-
son with the other compounds discussed in this overview
challenging.
CEA
Serum expression of carcinoembryonic antigen (CEA,
CD66e, CEACAM5) has been known for some time to be a
prognostic biomarker in PDAC, albeit with rather poor sensi-
tivity and specificity [77]. Boonstra et al. used a single chain
antibody fragment (scFv) that binds to CEA and labelled it
with the near-infrared fluorescent dye 800CW [78], and eval-
uated it in a mouse model of colorectal cancer (Fig. 9). High
tumour-to-background ratios were found 72 h after intrave-
nous administration in mice bearing subcutaneous xenografts.
Uncharacteristically for a single chain fragment, pharmacoki-
netics were rather slow, and liver uptake was high relative to
other organs. In another study by the same authors, a correla-
tion was found between serum CEA levels and PDAC tumour
expression of CEA, allowing selection of PDAC patients who
might benefit from CEA-targeted imaging [79].
A bispecific engineered antibody for pretargeted imaging
of CEA in combination with a radiolabelled hapten (111In-
IMP288) has been evaluated in a series of studies up to a
first-in-man study [80]. This followed earlier in vitro and pre-
clinical studies by Rossi et al. [81], Goldenberg et al. [82] and
Fig. 6 68Ga-avebehexin PET image (maximum-intensity projection,
60 min after injection) of a H2009-bearing SCID mouse. The tumour is
indicated by the arrow. Blad. bladder, Kid. kidneys [63]
Fig. 7 Coronal small-animal PET images of HT29 tumour-bearing im-
munodeficient mice injected with 68Ga-8, a radiolabelled neurotensin
peptide analogue. The mouse on the right received a blocking dose of
cold, unlabelled compound to saturate the receptor [71]
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Schoffelen et al. [83]. They showed good targeting of CEA-
expressing lymph node metastases in patients with colorectal
cancer (Fig. 10), suggesting that pretargeting may be an ex-
cellent way to circumvent the unfavourable liver, spleen and
intestinal uptake of other molecular imaging agents. PDAC
imaging has yet to be explored using this system.
CA19.9
Another innovative and promising area of work is that on
imaging CA19.9 in the local tumour environment. CA19.9
levels in blood serum are used clinically as a PDAC biomark-
er, but with limited sensitivity. However, CA19.9 originates in
the PDAC tissue itself, and local concentrations within the
tumour are therefore many times higher than circulating
levels. Houghton et al. therefore tagged the fully human
monoclonal anti-CA19.9 antibody 5B1 in a site-specific man-
ner with DFO for 89Zr labelling, or with a near-infrared dye
[84, 85]. Even though the modified antibodies showed a rela-
tively poor affinity for their target (Kd = 51 nM), they showed
excellent uptake in CA19.9-positive BxPC-3, yet negligible
uptake in negative control tumours not expressing CA19.9
(tumour uptake up to 102 ± 26%ID/g in subcutaneous
BxPC3 tumour xenografts, with tumour-to-blood ratios as
high as 20:1), and good uptake in orthotopic PDAC xeno-
grafts (40%ID/g; Fig. 11). The radiolabelled construct is
now under evaluation in clinical trials [57].
Imaging drug delivery, drug efficacy: gemcitabine
delivery/resistance
Most of the work discussed above focused on the develop-
ment of diagnostic or prognostic molecular imaging agents, or
looked at the specificity of potentially therapeutic antibodies.
However, another major challenge in PDAC patients is the
lack of response to the chemotherapy agents that are currently
employed to kill the tumour cells, and remain standard clinical
practice. To tackle this challenge, several groups have looked
at using molecular imaging to monitor a drug’s effects, or
alternatively have sought to radiolabel the drugs themselves,
Fig. 8 a Representative in-vivo
image of a human primary pan-
creatic cancer tumour xenograft in
a mouse after administration of a
Cy5 fluorophore-labelled cathep-
sin E substrate [74]. b A Cy5.5-
labelled cathepsin B-targeting
DARPin is taken up in a 4T1 al-
lograft murine breast tumour (red
circle), but not in a healthy mam-
mary fat pad (black circle) [75]
Fig. 9 NIR fluorescence imaging
in a mouse bearing subcutaneous
PDAC tumours acquired 72 h
after injection of CEA-targeting
ssSM3E/800CWor F73/800CW
[78]
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and so visualize their delivery, or indeed the absence thereof.
Belowwe briefly describe some recent work on imagingDNA
damage and on the delivery of gemcitabine.
γH2AX
Knight et al. found that targeting of the DNA damage marker,
γH2AX, predicted the response to chemotherapy using 5-FU,
gemcitabine or capecitabine [13]. These authors demonstrated
that uptake of a 89Zr-labelled anti-γH2AX antibody modified
with a cell-penetrating peptide, TAT, was significantly higher
in subcutaneous PDAC allograft tumours of mice that had
received chemotherapy than in vehicle-treated mice. 18F-
FDG, on the other hand, did not provide a useful indication
of therapeutic response (Fig. 12).
Radiolabelled nucleotide analogues
Chemotherapy agents used for the treatment of PDAC includ-
ed nucleotide analogues, such as 5-FU, gemcitabine and cap-
ecitabine. The inability of these compounds to accumulate in
PDAC tissue due to the intense desmoplastic reaction has led
some groups to develop radiolabelled analogues of these
drugs to study tumour delivery. This is especially relevant
given the numerous clinical trials attempting to target the stro-
mal tissue density in PDAC for therapeutic gain [86]. Liang et
al. [87] developed a radiolabelled gemcitabine analogue, 18F-
FAC, and also a deoxycytidine kinase (DCK) substrate. They
demonstrated that 18F-FAC accumulates selectively in DCK-
positive tumour xenografts. Furthermore, 18F-FAC PET imag-
ing predicted the response to gemcitabine. Russell et al.
showed that 18F-L-FAC uptake in orthotopically grown
PDAC xenografts correlated well with the delivery of a 14C-
labelled isotopologue of gemcitabine [88]. The high uptake of
18F-FAC in the intestinal lining and in inflamed tissue [90]
may, however, be a disadvantage for PDAC imaging, where
pancreatitis is ever present, yet certainly provides a tool for
assessing drug delivery.
Challenges
Despite these recent advances, a great number of challenges
remain in the molecular imaging of PDAC. In general, there is
a well-recognized lack of validated biomarker epitopes to use
as targets for imaging agents (or imaging biomarkers). A re-
cent EORTC panel review comprehensively highlighted these
as the need for: technical assay validation and GMP
Fig. 11 PET, PET/CT, and near
infrared imaging in an orthotopic
PDACmouse model using a 89Zr-
labelled anti-CA19.9 antibody
(LN lymph node, M metastasis, T
tumour) [84]
Fig. 10 a CEA expression in
human PDAC tissue (protein atlas
[56]) b SPECT/CT image in a 38-
year-old patient acquired 24 h af-
ter injection of 111In-IMP288
(185MBq, 25μg) pretargeted
with 75mg of TF2 (1-day
interval) [80]
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production of the imaging agent; biological and clinical vali-
dation in multiple model systems and in multiple centres; as-
sessment of cost effectiveness; standardization across centres
including accreditation systems; and, finally, the need for on-
going re-evaluation of the precision of an imaging biomarker
[90]. Not all of the imaging targets discussed above have been
stringently evaluated against these criteria. Most pressingly,
imaging targets should be validated using patient samples,
for example using immunohistochemistry. For PDAC, limited
access to these samples is often a major obstacle. Given the
need for large, multicentre trials to finally validate imaging
agents for PDAC, the cost and therefore the feasibility of these
studies become a limiting factors.
The wide variety of PDAC imaging agents that have been
explored preclinically exemplifies the lack of one clear bio-
marker or target for PDAC imaging. Direct comparison be-
tween imaging agents is severely complicated by: (1) the
lack of quantitative information regarding relative
(over)expression of the various epitopes for imaging in
PDAC versus normal pancreatic tissue, (2) the lack of quan-
titative data regarding the affinity of some of the imaging
agents, and (3) the variety of preclinical models that have
been used to evaluate these imaging agents. The eventual
choice of imaging agent will be informed by a combination
of the relevance of the target epitope, tumour-to-
background contrast, and tumour uptake.
Another challenge is the use of a suitable animal model to
predict the usefulness of an imaging agent for the human
disease. Subcutaneous xenograft models are a far cry from
the complexity of PDAC. They provide an excellent platform
for providing proof-of-principle of an imaging agent, but may
offer unrealistic levels of target epitope expression relative to
clinical presentation, a measure that is seldom quantified. On
the other hand, orthotopic implantation of PDAC cancer cells
seems underused in molecular imaging, although this model
does show some of the complications such as desmoplastic
responses seen in the clinic. Only a few genetically engineered
animal models of pancreatic cancer that replicate the human
disease exist [91], and of these, the KPC mouse model is by
far the most used, and is the only one to have been employed
in nuclear medicine imaging [88, 92, 93]. However, access to
these often complex and expensive models is a key limiting
factor [94]. To accurately compare different developments,
there is a need for standardization of the animal models used.
Additionally, imaging in patient-derived xenograft models
(PDX) may provide many benefits for evaluating the response
to therapy in an individual patient [94], but requires a logisti-
cally intricate setup.
The existence of desmoplasia, the build-up of stiff tissue
with overproduction of extracellular matrix proteins around
the tumour site, is a challenge for PDAC imaging both in
the clinic and in preclinical mouse models. It is believed that
desmoplasia can severely limit blood supply, and it has been
suggested as a major factor in limiting the delivery of blood-
borne imaging agents, as well as drugs, to the tumour site. The
various preclinical PDAC tumour models also show different
levels of desmoplasia, further complicating direct comparison
between imaging agents and models. Desmoplasia is least
evident in subcutaneous xenografts, highlighting the care that
should be taken in extrapolating preclinical results to the clin-
ic. Interestingly, this desmoplasia does not seem to be an issue
for even a large antibody-based CA19.9 imaging probe, either
in orthotopic xenografts or in patients with PDAC [57, 84,
85]. These seemingly opposing findings indicate that more
insight into the relationship of PDAC vascularity and delivery
of imaging agents is required.
Since the pancreas is a deep-seated organ in close proxim-
ity to the liver and intestines and because metastases occur in
the liver, there is a need for imaging agents with a ‘clean’
elimination profile, preferably with a renal excretion pattern.
To meet these pharmacokinetic requirements, renally cleared
small molecules, peptides and nanobodies, as well as
pretargeting techniques, need to be developed rather than
using directly radiolabelled antibodies. The latter show signif-
icant liver uptake and may hinder the detection of ubiquitous
liver metastases.
Finally, the cost of nuclear medicine procedures in the man-
agement of patients with pancreatic cancer should be ad-
dressed. The cost of such a procedure must beweighed against
the potential benefits, e.g. extending life expectancy or en-
hancing quality of life. For early detection of PDAC, molec-
ular imaging could close the diagnostic sensitivity gap
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Fig. 12 Monitoring 5-FU therapy with 89Zr-anti-γH2AX-TAT: PET/CT
images show coronal (top) and transaxial (bottom) sections intersecting
the centre of the allograft tumour (dotted circles) [13]. Tumour uptake of a
nonspecific control antibody (RIgG) was not different between 5-FU-
treated and vehicle-treated animals
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between small, undetectable, or even premalignant disease,
and lesions visible on CTorMR and could assist in improving
the identification of patients who could benefit from radical
treatments including radiochemotherapy as well as surgery.
Likewise, the benefits of an imaging procedure that allows
early detection of a failing therapy (in more than 90% of
patients [95]) far outweigh the cost of continuing ineffective
therapy, in terms of both the financial cost and its effect on the
patient’s quality of life and treatment-related morbidity/
mortality.
Conclusion
In the field of pancreatic cancer research, much despondency
during the past 40 years is now givingway to quiet enthusiasm
due to new investment and developments in basic research,
biomarker discovery and novel therapy combinations. We are
strongly of the opinion that nuclear medicine will play a big
role in this field. The ‘right’ choice of imaging agent is still a
matter of debate, with a wide variety of tools being developed
targeting an equally wide range of signalling pathways in-
volved in PDAC. Unfortunately, most novel and potentially
game-changing imaging approaches remain untested clinical-
ly, or even lack verification of the validity of the imaging
target in clinical samples, and much work remains to verify
the clinical applicability of imaging agents.
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